中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

43 records (took 0.029 seconds)

    클로로이미다졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 또는 비만의 예방 또는 치료용 약학적 조성물
    12.
    发明公开
    클로로이미다졸 유도체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 골다공증 또는 비만의 예방 또는 치료용 약학적 조성물 失效
    用于预防或治疗包含氯霉素衍生物的药物或药物的药物组合物或其作为活性成分的药物可接受的盐

    公开(公告)号：KR1020100130015A

    公开(公告)日：2010-12-10

    申请号：KR1020090048661

    申请日：2009-06-02

    Applicant: 한국화학연구원

    Inventor： 김낙정 ,  배명애 ,  유성은 ,  강남숙 ,  허정녕 ,  이규양 ,  서지희 ,  황은숙 ,  홍정호

    IPC: C07D487/04 ,  C07D487/02 ,  A61K31/415 ,  A61P19/10

    Abstract: PURPOSE: A pharmaceutical composition containing chloroimidazole derivative for preventing or treating osteoporosis, obesity, diabetes or hyperlipidemia is provided to control TAZ(transcriptional coactivator with PDZbinding motif) protein. CONSTITUTION: A pharmaceutical composition for preventing or treating osteoporosis contains a compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A pharmaceutical composition for obesity, diabetes or hyperlipidemia contains the compound or pharmaceutically acceptable salt as an active ingredient. The compound is chloroimidazole derivatives.

    Abstract translation: 目的：提供含有用于预防或治疗骨质疏松症，肥胖，糖尿病或高脂血症的氯咪唑衍生物的药物组合物以控制TAZ（具有PDZ结合基序的转录共激活物）蛋白质。 构成：用于预防或治疗骨质疏松症的药物组合物含有化学式1的化合物或其药学上可接受的盐作为活性成分。 用于肥胖，糖尿病或高脂血症的药物组合物含有化合物或药学上可接受的盐作为活性成分。 该化合物是氯咪唑衍生物。

    불소 함유 피리디니움 옥심 유도체 또는 약학적으로 허용가능한 이의 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
    13.
    发明公开
    불소 함유 피리디니움 옥심 유도체 또는 약학적으로 허용가능한 이의 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 失效
    含有氟或其药学上可接受的盐的吡啶鎓衍生物，其制备方法和含有其的药物组合物

    公开(公告)号：KR1020100067302A

    公开(公告)日：2010-06-21

    申请号：KR1020080125791

    申请日：2008-12-11

    Applicant: 한국화학연구원

    Inventor： 정영식 ,  강남숙 ,  채종학 ,  박노상 ,  박노중

    IPC: C07D403/08 ,  C07D403/02

    Abstract: PURPOSE: A fluorine-containing pyridinium oxime derivative is provided to reactivate acetylcholine esterase and to use as a detoxifying agent. CONSTITUTION: A fluorine-containing pyridinium oxime derivative is denoted by chemical formula 1. In chemical formula, R is hydrogen or fluorine; Y is CH=N-OH or C(=O)-NH_2, at least one among Y is CH=N-OH; and X is Cl, Br, I, OS(=O)_2CH_3 or OS(=O)_2CF_3. An detoxifying agent against organic phosphorus chemical contains fluorine-containing pyridinium oxime derivative as an active ingredient. A therapeutic agent to organic phosphorus agricultural chemical contains fluorine-containing pyridinium as an active ingredient.

    Abstract translation: 目的：提供含氟吡啶鎓肟衍生物以使乙酰胆碱酯酶重新活化并用作解毒剂。 构成：含氟吡啶鎓肟衍生物由化学式1表示。在化学式中，R为氢或氟; Y是CH = N-OH或C（= O）-NH 2，Y中的至少一个是CH = N-OH; X是Cl，Br，I，OS（= O）_2CH_3或OS（= O）_2CF_3。 针对有机磷化合物的解毒剂含有含氟吡啶鎓肟衍生物作为活性成分。 有机磷农药的治疗剂含有含氟吡啶鎓作为活性成分。

    1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물
    16.
    发明授权
    1,2,4-티아다이아졸리딘-3,5-다이온 화합물을 포함하는염증관련 질환의 치료 및 예방을 위한 약제학적 조성물 失效
    用于治疗或预防包含1,2,4-噻二唑-3,5-二酮化合物的药物的药物组合物

    公开(公告)号：KR100837785B1

    公开(公告)日：2008-06-13

    申请号：KR1020070005148

    申请日：2007-01-17

    Applicant: 한국화학연구원

    Inventor： 이계형 ,  원종화 ,  김익연 ,  노재성 ,  김지영 ,  원혜경 ,  정은주 ,  허민규 ,  김성주 ,  김영림 ,  전동주 ,  송종환 ,  강남숙 ,  유성은

    IPC: A61K31/4152 ,  A61P29/00

    CPC classification number: A61K31/433 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/5377 ,  Y10S514/825 ,  Y10S514/886

    Abstract: A novel 1,2,4-thiadiazolidine-3,5-dione compound is provided to show excellent activity and enzyme selectivity on Lck SH2, thereby being usefully used for treating and preventing inflammation related diseases such as rheumatoid arthritis with high selectivity without side effects. A pharmaceutical composition for treating and preventing a disease induced by inflammation comprises a 1,2,4-thiadiazolidine-3,5-dione compound represented by a formula(1) or a pharmaceutically acceptable salt thereof as an effective ingredient. In the formula(1), A is linear or branched saturated or unsaturated C1-7 alkyl, indenyl, (C1-7)alkoxycarbonyl(C1-7)alkyl, phenyl, benzyl or C2H5(C=O)HR2R3(wherein A may be substituted by halogen, carboxyl, C1-7 alkoxycarbonyl, C1-7 alkoxy, nitro or hydroxy when A is alkyl, phenyl or benzyl); R1 is H, linear or branched saturated or unsaturated C1-7 alkyl, (C1-7)alkoxycarbonyl(C1-7)alkyl, phenyl, phenyl(C1-5)alkyl or phenylcarbonylmethyl; and each R2 and R2 is independently H, linear or branched saturated or unsaturated C1-7 alkyl or phenyl, or R2 and R3 may form a ring together with C1-5 alkylene. A pharmaceutical composition for treating and preventing rheumatoid arthritis comprises the 1,2,4-thiadiazolidine-3,5-dione compound of the formula(1) or a pharmaceutically acceptable salt thereof as an effective ingredient.

    Abstract translation: 提供了一种新的1,2,4-噻二唑烷-3,5-二酮化合物，以显示对Lck SH2的极好的活性和酶选择性，从而有效地用于治疗和预防炎症相关疾病如类风湿性关节炎，具有高选择性，无副作用 。 用于治疗和预防炎性疾病的药物组合物包含由式（1）表示的1,2,4-噻二唑烷-3,5-二酮化合物或其药学上可接受的盐作为有效成分。 在式（1）中，A是直链或支链饱和或不饱和的C1-7烷基，茚基，（C1-7）烷氧基羰基（C1-7）烷基，苯基，苄基或C2H5（C = O）HR2R3（其中A可以 苯基或苄基）被卤素，羧基，C 1-7烷氧基羰基，C 1-7烷氧基，硝基或羟基取代。 R1是H，直链或支链饱和或不饱和的C1-7烷基，（C1-7）烷氧基羰基（C1-7）烷基，苯基，苯基（C1-5）烷基或苯基羰基甲基; 并且每个R 2和R 2独立地为H，直链或支链饱和或不饱和的C 1-7烷基或苯基，或者R 2和R 3可与C 1-5亚烷基一起形成环。 用于治疗和预防类风湿性关节炎的药物组合物包含式（1）的1,2,4-噻二唑烷-3,5-二酮化合物或其药学上可接受的盐作为有效成分。

    피리다지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물
    19.
    发明公开
    피리다지논 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 약학적 조성물 有权
    吡咯烷酮衍生物或其药学上可接受的盐，其制备方法和包含其的药物组合物

    公开(公告)号：KR1020120109877A

    公开(公告)日：2012-10-09

    申请号：KR1020110027656

    申请日：2011-03-28

    Applicant: 한국화학연구원

    Inventor： 김낙정 ,  강남숙 ,  김성환 ,  유성은 ,  이규양 ,  서지희 ,  임채조 ,  황순희

    IPC: C07D237/14 ,  C07D401/04 ,  A61K31/50 ,  A61P5/26

    Abstract: PURPOSE: A pharmaceutical composition containing pyridazinone derivatives is provided to effectively suppress cancer cell growth and to prevent or treat benign prostatic hyperplasia, acne, sterility, or male pattern baldness. CONSTITUTION: A pyridazinone derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing or treating androgen-associated diseases contains the derivatives of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition is administered in the form of a tablet, pill, soft/hard capsule, liquid, suspension, emulsion, syrup, granule, elixir, or troche by oral administration and hypodermic injection, intravenous injection, intramuscular injection by parenteral administration.

    Abstract translation: 目的：提供含有哒嗪酮衍生物的药物组合物，以有效抑制癌细胞生长并预防或治疗良性前列腺增生，痤疮，不育或男性型秃发。 构成：哒嗪酮衍生物由化学式1表示。用于预防或治疗雄激素相关疾病的药物组合物含有化学式1的衍生物或其药学上可接受的盐作为活性成分。 药物组合物通过口服给药和皮下注射，静脉内注射，通过肠胃外给药肌内注射，以片剂，丸剂，软/硬胶囊，液体，悬浮液，乳剂，糖浆，颗粒剂，酏剂或锭剂的形式给药。

Patent Agency Ranking